Can Melatonin Lower High Blood Pressure? Nighttime Dosing Evidence

Melatonin can modestly lower nighttime blood pressure in some people, particularly those with nocturnal hypertension, but it is not an established antihypertensive therapy. Meta-analyses of randomized trials report average nighttime systolic reductions of roughly 3-6 mmHg and smaller daytime effects, with a 2022 pooled analysis finding sleep-time systolic declines of about 4 mmHg at typical 2-5 mg doses. Effects are inconsistent across trials, depend heavily on timing and formulation, and no cardiology guideline lists melatonin as a treatment for high blood pressure. Melatonin is a plausible adjunct for select patients, not a replacement for proven therapy.

How Melatonin Signals Blood Vessels to Relax

Melatonin is not a sedative that indirectly lowers pressure through sleep. It binds specific receptors on the vascular wall and acts as a direct vasodilator. Two receptor subtypes, MT1 and MT2, are expressed in both central brain regions and peripheral arteries, and activation of the endothelial MT2 receptor triggers nitric oxide release. Nitric oxide diffuses into smooth muscle cells, raises cyclic GMP, and reduces intracellular calcium, which relaxes the vessel and widens its lumen.

The pressure effect of that cascade is small but measurable. In forearm blood-flow studies, local melatonin infusion increases vasodilation by roughly 20-30 percent in healthy adults, an effect blocked by a melatonin-receptor antagonist. That confirms a receptor-specific mechanism rather than a general calming effect. In plain terms: melatonin talks directly to the artery wall, not just to the sleep centers.

A second pathway runs through the sympathetic nervous system. Melatonin blunts nighttime sympathetic outflow, reducing the surge in catecholamines that normally keeps pressure from falling adequately during sleep. Animal work shows melatonin administration lowers heart rate and vascular resistance during the dark phase, an effect partly independent of sleep itself. This matters because nocturnal blood pressure is regulated by a different set of drivers than daytime pressure.

A third, more speculative mechanism involves the antioxidant and anti-inflammatory actions of melatonin at the vascular endothelium. Chronic low-grade inflammation stiffens arteries, and melatonin's free-radical scavenging may slow that process over months. This pathway is biologically plausible but has not been demonstrated to produce clinically meaningful pressure changes in human trials, and it should be treated as hypothesis rather than established fact.

The Nighttime Numbers: What Trials Actually Show

The strongest signal for melatonin and blood pressure appears at night, not during the day. This is consistent with the mechanism, since endogenous melatonin peaks in the dark phase and the drug is usually taken at bedtime. A meta-analysis of randomized controlled trials published in 2022 pooled data from adults with and without hypertension and found sleep-time systolic pressure reductions averaging about 4 mmHg, with diastolic reductions of roughly 2-3 mmHg.

The size of that effect places melatonin in a specific tier. A 4 mmHg nighttime systolic reduction is comparable to what a low-dose thiazide or a modest dietary sodium restriction produces, but it is far below the 10-20 mmHg reductions achievable with standard antihypertensive drugs. For context, each 10 mmHg reduction in systolic pressure is associated with roughly a 20 percent lower risk of major cardiovascular events in epidemiological analyses. A 4 mmHg change is meaningful at the population level but marginal for an individual.

Nighttime dosing trials show a timing dependence that daytime dosing trials do not. Studies giving melatonin 30-60 minutes before sleep report the largest nocturnal reductions, while trials dosing in the morning often find no significant effect or even a slight pressor response. The table below summarizes the range of effects reported across trial designs, with the caveat that individual trial results vary widely and some report no significant change at all.

The Nocturnal Blood Pressure Problem Melatonin Addresses

Roughly 25-30 percent of adults with hypertension are "non-dippers," meaning their blood pressure fails to fall by the normal 10-20 percent during sleep. Non-dipping is associated with a substantially higher risk of stroke, heart failure, and kidney disease, independent of daytime pressure readings. Because standard clinic measurements miss nocturnal pressure entirely, non-dipping often goes undetected for years.

Melatonin's nocturnal action makes it mechanistically attractive for this group. Several small trials in non-dippers found that bedtime melatonin improved the dipping pattern, converting some patients to dippers, with nighttime systolic reductions of 5-8 mmHg in the better-designed studies. One crossover trial in patients with nocturnal hypertension reported that controlled-release melatonin 2 mg reduced nighttime systolic pressure by about 6 mmHg compared with placebo.

That 6 mmHg figure should not be generalized. The trials are small, often single-center, and use different formulations, doses, and inclusion criteria. Some trials in non-dippers found no significant improvement in dipping status despite modest pressure reductions. The consistent thread is a nighttime-predominant effect; the inconsistent thread is its magnitude and whether it changes clinical outcomes.

Melatonin Compared With Standard Pressure Strategies

Melatonin occupies a narrow niche relative to established interventions. The comparison below places its typical effect in context. The numbers are approximate population averages from trial and guideline literature, and individual responses vary considerably.

The pattern is clear. Melatonin's effect size overlaps with lifestyle measures but sits well below pharmacologic therapy. Its distinguishing feature is selectivity for nighttime pressure, which is exactly where standard clinic readings are blind. That makes melatonin a reasonable subject of discussion for patients with confirmed nocturnal hypertension, and a poor substitute for proven drugs in anyone with sustained daytime elevation.

Where the Evidence Is Weak and the Claims Outrun It

The most common misconception is that melatonin is a proven antihypertensive. It is not. No major cardiology guideline, including the 2017 ACC/AHA hypertension guideline, lists melatonin as a treatment option. The evidence base consists of small trials with heterogeneous designs, not the large outcome trials required to establish a therapy. Claiming melatonin "lowers high blood pressure" as a general statement overstates what the data support.

A second misconception concerns dose. More melatonin is not better, and the dose-response curve may actually be flat or inverted. Most positive trials used 2-5 mg, while higher doses in some studies failed to outperform placebo. Melatonin's effects may be receptor-saturating, meaning 10 mg adds side effects without added benefit. The FDA does not regulate melatonin as a drug, so label doses can vary substantially from actual content, and independent testing has found discrepancies in some products.

A third issue is timing and formulation. Immediate-release melatonin peaks in the blood within 60 minutes, while controlled-release formulations sustain levels for 6-8 hours. The nocturnal blood pressure effect depends on maintaining receptor activation through the night, which favors controlled-release products in trials targeting nighttime pressure. Taking melatonin in the morning, or taking an immediate-release product too early, may miss the window entirely.

A fourth caveat is drug interaction. Melatonin is metabolized by CYP1A2, and drugs that inhibit this enzyme, including fluvoxamine and some quinolone antibiotics, can raise melatonin levels several-fold. Melatonin can also interact with warfarin, immunosuppressants, and some diabetes medications. These interactions are uncommon but clinically relevant for patients on multiple drugs, and they are a reason not to self-dose without discussion.

Practical Steps for Patients Considering Melatonin

For someone with confirmed or suspected nocturnal hypertension who wants to explore melatonin, the sensible approach is structured rather than casual. The following steps reflect what the trial evidence supports and what a careful clinician would consider.

• Confirm the problem first. Ask for 24-hour ambulatory blood pressure monitoring, because a bedtime melatonin trial without baseline nighttime data cannot be evaluated. A single clinic reading will not show nocturnal pressure.
• Choose controlled-release 2-5 mg taken 1-2 hours before sleep. Immediate-release products peak too early for a full-night effect, and doses above 5 mg have not shown added benefit in trials.
• Track nighttime pressure with a home device that records during sleep, or repeat ambulatory monitoring after 4-6 weeks. Effects, if any, should appear within that window.
• Do not stop or reduce prescribed antihypertensives. Melatonin's effect size is too small to replace standard therapy, and abrupt discontinuation of proven drugs carries real risk.
• Check for interactions with a pharmacist if you take fluvoxamine, warfarin, immunosuppressants, or diabetes medications.
• Treat sleep apnea as a separate problem. If snoring, daytime fatigue, or witnessed apneas are present, melatonin will not fix the underlying pressure driver.

The bulleted red flags below warrant medical evaluation before any self-treatment, because they may indicate a cause of hypertension that melatonin cannot address.

• Blood pressure above 180/120 mmHg at any time
• New headache, chest pain, shortness of breath, or vision change
• Confirmed sleep apnea with daytime sleepiness
• Kidney disease or known secondary causes of hypertension
• Pregnancy or planned pregnancy

Limitations and Honest Bottom Line

The honest summary is that melatonin has a real but modest nighttime blood pressure effect, supported by small trials and plausible mechanisms, and insufficient evidence to justify use as a primary treatment. The effect size of roughly 3-6 mmHg nighttime systolic reduction overlaps with lifestyle interventions and falls short of standard drugs. The evidence is strongest for patients with nocturnal hypertension or non-dipping patterns, and weakest for general claims about "lowering high blood pressure."

Three limitations deserve emphasis. First, no trial has been large enough or long enough to show that melatonin reduces cardiovascular events, so any benefit is inferred from surrogate pressure readings. Second, formulations and doses vary widely, and product quality is not guaranteed, which makes replication of trial results uncertain in practice. Third, the interaction between melatonin and endogenous circadian rhythm means effects may differ in shift workers, older adults with reduced melatonin production, and people with sleep disorders.

Melatonin is best understood as a circadian signal with vascular side effects, not a blood pressure drug. That framing keeps expectations calibrated. It can be a reasonable adjunct for a patient with confirmed nocturnal hypertension who has discussed it with a clinician, taken at the right dose and timing, with objective monitoring to confirm whether it helps. It is not a substitute for proven therapy, and it should not delay evaluation of the underlying causes of high blood pressure. The mechanism is real, the numbers are modest, and the evidence is promising but incomplete.